98%
921
2 minutes
20
Background: Erysipeloid cutaneous leishmaniasis (ECL) is known as the chronic form of cutaneous leishmaniasis (CL). However, keeping its clinical presentation in view, there is a need to revisit this form of the disease.
Aims: To describe ECL in view of clinical features and treatment modalities.
Methods: We include a case series seen in Sfax (Southern Tunisia) from January 2017 to January 2021. All patients clinically suggestive and laboratory confirmed with a diagnosis of CL were registered. Patients of all age groups and of either gender having cutaneous lesions resembling erysipela on the face were included in the study. Different demographic features of the patients and clinical aspects were identified. Descriptive statistics were used for analysis.
Results: Of 1300 registered patients with CL, 40 (3%) were diagnosed as ECL. Ages ranged from 15 to 65 years, and duration of lesions varied from 15 to 180 days. All patients had lesions over the face. Clinically, a painful infiltrated inflammatory placard of the central facial area with a butterfly shape was observed in 14 cases, as well as zones of the cheekbone (11 cases), cheekbone and nose (5 cases), cheekbone and eyelid (8 cases), and cheekbone with ear (2 cases). Several therapeutic methods were prescribed with a sufficient result with no recurrence.
Conclusion: ECL is a rare presentation that typically occurs on the face, looking like erysipelas, in patients who are native from an endemic region of CL.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/ijd.16278 | DOI Listing |
Trop Med Int Health
September 2025
Diretoria de Pesquisa e Desenvolvimento, Fundação Ezequiel Dias, Minas Gerais, Brazil.
Introduction: In recent years, the global burden of tegumentary leishmaniasis (TL) has significantly increased in the Americas.
Objective: To estimate the prevalence of TL in South America based on publications from the past 13 years.
Methods: Three databases were searched, and articles were selected based on inclusion criteria and methodological relevance.
Turkiye Parazitol Derg
September 2025
Ege University Faculty of Medicine, Department of Parasitology, İzmir, Türkiye.
Objective: Leishmaniasis, caused by protozoan parasites of the spp., presents significant global health challenges, with visceral leishmaniasis (VL) and cutaneous leishmaniasis forms causing severe morbidity and mortality. Macrophages serve as primary host cells, where spp.
View Article and Find Full Text PDFTravel Med Infect Dis
September 2025
Hospital for Tropical Diseases, University College London Hospitals NHS Foundation Trust. London, UK; Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK.
Introduction: Leishmaniasis is a parasitic disease caused by protozoa of the genus Leishmania. Disease phenotypes are heterogenous, and diagnosis is frequently delayed. Treatment is often challenging, and international guidelines recommend consultation with experts.
View Article and Find Full Text PDFIndian J Med Microbiol
September 2025
Vedanta Inst. of Medical Sciences, Navarangpura, Ahmedabad, 380009, India. Electronic address:
Cutaneous leishmaniasis is endemic in more than 98 countries, and in India it was described in the Thar Desert in Rajasthan and parts of the Gangetic Plain. Many other states, notably Kerala, Jammu and Kashmir, Himachal Pradesh, and others, have been emerging endemic foci for cutaneous leishmaniasis in India. We are reporting the first autochthonous case of cutaneous leishmaniasis and adding the state of Gujarat to this list of emerging endemic areas for cutaneous leishmaniasis.
View Article and Find Full Text PDFJAAD Case Rep
October 2025
Department of Dermatology, Medical University of Vienna, Vienna, Austria.